Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/341968
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampDelamain, Marcia Torresan-
dc.typeArtigopt_BR
dc.titleOutcomes of HIV-associated Burkitt Lymphoma in Brazil: high treatment toxicity and refractoriness rates – a multicenter cohort studypt_BR
dc.contributor.authorSilva, W.F.D.-
dc.contributor.authorGaribaldi, P.M.M.-
dc.contributor.authorRosa, L.I.D.-
dc.contributor.authorBellesso, M.-
dc.contributor.authorClé, D.V.-
dc.contributor.authorDelamain, M.T.-
dc.contributor.authorRego, E.M.-
dc.contributor.authorPereira, J.-
dc.contributor.authorRocha, V.-
dc.subjectQuimioterapiapt_BR
dc.subject.otherlanguageChemotherapypt_BR
dc.description.abstractAlthough the increased use of combined antiretroviral therapy (cART) has decreased the incidence of lymphomas HIV-associated, Burkitt lymphoma (BL) incidence remains stable. Reported outcomes on HIV-associated BL from developed countries seem to corroborate that the regimens do not need to be tailored to the HIV-positive population. Materials and methods: This is a retrospective multicenter cohort study from Brazil, including HIV-positive patients aged 15 years and above diagnosed with BL. Results: A total of 54 patients were included. Median age was 39 years (range, 15–64). At diagnosis, advanced disease was found in 86% and 52% had a CD4+ count lower than 200 cells/mm3. Five patients died before starting any regimen. Among the remaining 49 patients, most were treated with Hyper-CVAD (53%) and CODOX-M IVAC (18%). Rituximab was used in frontline in only 16% of the patients. Primary refractory disease was found in 14%. A treatment-related mortality of 38.7% and a complete response rate of 44.9% were found. At 4 years, estimated overall survival (OS) was 39.8%. All relapsed and primary refractory patients eventually died. Remaining patients died from infections (24/34), despite antimicrobial prophylaxis and associated cART. Conclusion: Early mortality and toxicity were higher in our cohort than in developed countries. A faster diagnosis, better understanding of the biology of the disease, establishment of low toxicity regimens, inclusion of rituximab and improvement of supportive care may decrease the mortality of HIV-associated BL in developing countriespt_BR
dc.relation.ispartofLeukemia researchpt_BR
dc.relation.ispartofabbreviationLeuk. res.pt_BR
dc.publisher.cityOxfordpt_BR
dc.publisher.countryReino Unidopt_BR
dc.publisherElsevierpt_BR
dc.date.issued2020-
dc.date.monthofcirculationFeb.pt_BR
dc.language.isoengpt_BR
dc.description.volume89pt_BR
dc.rightsFechadopt_BR
dc.sourceSCOPUSpt_BR
dc.identifier.issn0145-2126pt_BR
dc.identifier.eissn1873-5835pt_BR
dc.identifier.doi10.1016/j.leukres.2019.106287pt_BR
dc.identifier.urlhttps://www.sciencedirect.com/science/article/abs/pii/S0145212619307325pt_BR
dc.description.sponsordocumentnumbersem informaçãopt_BR
dc.date.available2020-05-21T21:56:01Z-
dc.date.accessioned2020-05-21T21:56:01Z-
dc.description.provenanceSubmitted by Sanches Olivia (olivias@unicamp.br) on 2020-05-21T21:56:01Z No. of bitstreams: 0. Added 1 bitstream(s) on 2020-08-27T19:15:36Z : No. of bitstreams: 1 2-s2.0-85076860874.pdf: 783412 bytes, checksum: 9fc4938ac4d6c62496c48b568c1cdb87 (MD5)en
dc.description.provenanceMade available in DSpace on 2020-05-21T21:56:01Z (GMT). No. of bitstreams: 0 Previous issue date: 2020en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/341968-
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.subject.keywordBurkitt Lymphomapt_BR
dc.subject.keywordAIDS-related lymphomapt_BR
dc.subject.keywordSurvivalpt_BR
dc.subject.keywordDeveloping countriespt_BR
dc.identifier.source2-s2.0-85076860874pt_BR
dc.creator.orcid0000-0001-9071-4397pt_BR
dc.type.formArtigopt_BR
dc.identifier.articleid106287pt_BR
dc.description.otherSponsorshipsem informaçãopt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-85076860874.pdf765.05 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.